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Background: Very little data are available on the natural course or level of disturbance of vasomotor symptoms
among middle-aged women. Using readily collected trial data we studied the persistence of vasomotor symptoms
among untreated women.
Methods: In a trial comparing combined hormone therapy to placebo or no treatment (control groups), a cohort
of women aged 50–59 at recruitment were followed annually by questionnaires. Women in the control groups (n
= 486) were grouped by the number of years followed, with the prevalence and severity of symptoms calculated
both cross-sectionally and longitudinally.
Results: About two thirds of the women (67%) reported vasomotor symptoms and half (46%) bothersome
symptoms at recruitment. In the cross-sectional analysis, their prevalence declined between recruitment and 1-year
follow-up (32% bothersome symptoms) and 2-year follow-up (27%). Thereafter it remained about the same level. In
the longitudinal analysis, there was a notable variation in the prevalence of disturbing vasomotor symptoms over
time, time entering the study and the compliance to the surveys. In the two groups having most follow-up times,
the proportion of women with bothersome symptoms first increased and then decreased.
Conclusions: There was a notable variability in the development of disturbing vasomotor symptoms over time in a
selected group of women aged 50–59. Population-based follow-up studies of untreated women would be useful to
estimate the symptom burden.
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A number of studies have reported a high prevalence of
vasomotor symptoms among middle-aged women [1-5].
In a large review by the National Institutes of Health [6],
14–51% of premenopausal and 30–80% of peri- and
postmenopausal women reported hot flashes and night
sweats. However, not all women consider hot flushes
bothersome [5,7-10]. Sleep disturbances are common
among all menopausal women (occurring in 16–42% of
premenopausal, 39–47% of perimenopausal and 35–60%* Correspondence: elina.hemminki@thl.fi
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distribution, and reproduction in any mediumof postmenopausal women). In a Finnish population-
based study by Hemminki et al. (1995), 28% of women
aged 45–64 years reported hot flushes, 38% reported
tiredness and 27% different kind of pains (head-, back-,
and joint ache). The probability of other symptoms is
higher if the woman has vasomotor symptoms [7,11].
Cross-sectional surveys among women of different
ages show that hot flushes are most common soon after
menopause, but they occur even after 10 years
[7,8,12,13]. Some women have not flashes even before
menopause [13-15], and among some women they be-
come bothersome only some years after menopause [13].
The consensus around vasomotor symptoms (hot
flushes and sweating) and vaginal dryness—though nottral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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during menopause than before or after it [2,6,9,16-18].
Results conflict as to whether or not other complaints
are more common around menopause [16] or whether
the observed increase is related to age rather than to
menopause [2,19].
Very few studies grade the symptoms according to
women’s experience of disturbance or what is their pat-
terning [20]. The purpose of this study was to use readily
collected data on control women in a hormone therapy
trial to study how bothersome vasomotor symptoms are
for women and what is their patterning. Originally we
had also planned to study their duration, but the avail-
able data did not allow that.
Methods
This is a cohort study based on yearly follow-up ques-
tionnaires sent to control women of a trial comparing
combined hormone therapy to either placebo or nothing
(the control groups) [21]. Women were recruited in
Estonia from 1999–2001, and followed by annually
mailed questionnaires in 2000–2004. Detailed descrip-
tions of the recruitment, inclusion and exclusion criteria,
trial treatment, adherence, follow-up and trial outcomes
as well as the content of information leaflets and trial
questionnaires have been published elsewhere [21-24].
In the following the main features relevant to this study
are described.
A recruitment questionnaire was mailed in 1998–1999
to all women aged 45–64 in two Estonian counties (n =
39 713); the identification was through the Estonian
Population Registry. Of the 14 743 women who returned
the questionnaire, 6606 respondents were interested in
participating in a randomised trial, of which 4295
women were found to be eligible according to the pre-
liminary assessment. The eligibility criteria included age
of 50 to 64 and an elapsed time of 12 months or more
since the last period at the randomisation stage [21].
A personal invitation was mailed to eligible women in
1999–2001. A total of 2323 women responded to the in-
vitation to visit the trial doctor. After a secondary assess-
ment of eligibility, 1778 women proved to be eligible
and were willing to join the trial; 404 women were ran-
domized into the blind hormone therapy (HT) arm, 373
into the placebo arm, 494 into the non-blind HT arm
and 507 into the non-treatment arm [21,22]. The 46
women who participated in the pilot study are not
included in the present analysis. The women in the blind
arms received their drug bottles with coded labels
(otherwise identical bottles). Women in the non-blind
HT arm had their drug bottles marked with HT.
Only data on women in blind placebo group and non-
treatment group aged 50–59 at recruitment (n = 486) are
used in this study. Throughout the trial, about 90% ofwomen in the non-treatment group and 95% in the pla-
cebo group did not start hormone therapy [24]. The
power calculations were made for the main study [21-23],
but not for this cohort study based on the trial data.
All participants were mailed annual questionnaires
that included questions about their current life situation,
health, and use of health services. The response rate was
75% for the first annual survey, 69% for the second an-
nual survey, and 81% of the participants for the final sur-
vey mailed at the end of the trial and followed by one
reminder. On average, the final survey was completed
3.6 years after the recruitment. Each of the survey ques-
tionnaires had a list of 18 symptoms experienced in the
previous two weeks and an additional question asking
women to specify which they had found bothersome.
The questions concerning symptoms that were related
to menopause (translated into English) are given in
Additional file 1: Appendix 1.
All participants gave written informed consent. The
study protocol was approved by the Committee of Med-
ical Ethics in Tallinn, Estonia and by the Ethics Commit-
tee of the University Clinic of Tampere, Finland.
Analysis
The non-compliant women (about 9% of women used
hormone therapy for some time during the trial in the
control group) were included in this analysis. Results
were analyzed separately for those aged <55 years and
56–59 years old at recruitment, and as a combined age
group. For the longitudinal analysis, women were
grouped into 6 groups by the timing and order of
follow-up surveys they completed. The aim was for sur-
veys to be completed at 12-month intervals. However,
postal dispatch was done according to groups and the
time could be somewhat more or less than 12 months.
Furthermore, some women answered after some delay.
Thus, we first calculated for each woman the months
between the recruitment and the different surveys using
the date of filling in the questionnaire. We then grouped
the surveys as follows: 6–18 months = 1-year follow-up,
19–28 months = 2-year follow-up, 29–42 months = 3-
year follow-up, 43–59 months =4-year follow-up.
Women who left one or more follow-up surveys un-
answered formed a separate group (intermittent
surveys).
We classified women into those who had or had not
had symptoms in the following symptom groups: 1)
vasomotor symptoms (cold sweats, hot flashes), 2) psy-
chological symptoms (feeling blue or depressed, irritabil-
ity), 3) pains (backache, headache, stomach ache,
stiffness or joint pain). If a woman mentioned at least
one of the symptoms from a group, the woman was
categorized as having the symptoms of that group. If at
least one of these symptoms was said to be bothersome,
Table 2 Proportions (%) of women with vasomotor
symptoms and bothersome symptoms1 in past two
weeks, at each survey (cross-sectional analysis)
Recruitment 1-year 2-year 3-year 4-year
Women <55
number of women 182 129 124 64 22
(mean age) (52.7) (53.8) (54.9) (55.7) (56.4)
any 75.8 54.3 41.9 42.9 31.8
bothersome2 50.0 34.1 29.0 34.4 18.2
(of vasomotor3) (66.0) (62.8) (69.2) (80.2) (57.2)
All women (50–59)
Number of women 486 352 330 204 66
(mean age) (57.1) (56.6) (57.7) (58.8) (59.8)
any 67.3 53.1 43.0 42.9 45.5
bothersome2 45.7 32.4 27.0 24.0 24.2
(of vasomotor3) (67.9) (61.0) (62.7) (55.9) (53.2)
1 sweating and/or hot flashes.
2 at least one of the symptoms was bothersome, % of women.
3 women with bothersome vasomotor symptoms of women with any
vasomotor symptoms.
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toms of that group.
Results
Table 1 gives the background characteristics of the
women at recruitment. The mean age at recruitment
was 55 years (SD 2.5), most were married or cohabiting,
were well educated, and were urban dwellers. The two
age-groups were very similar by the studied background
characteristics.
Table 2 gives the prevalence of vasomotor symptoms
according to a cross-sectional analysis. At the time of re-
cruitment, about two thirds of the women reported
vasomotor symptoms, and about a half regarded them as
bothersome. In the survey a year later, less (53%) of
women reported vasomotor symptoms and a third found
them bothersome. In the surveys 2–4 years later, the
proportions reporting symptoms were lower (around
40%), while a fourth of the women reported them being
bothersome. The prevalence of women reporting bother-
some symptoms declined by 29% from recruitment to
the 1-year follow-up and by 41% to the 2-year follow-up.
Thereafter the prevalence of symptoms remained at
roughly the same level.
Table 3 gives the results of the longitudinal analysis in
which the same women were followed from one survey
to another. There were some differences by the number
of follow-ups (how early or late the woman was
recruited) as well as by compliance with the surveys (did
she skip some of the surveys, group “Intermittent sur-
veys” in Table 3). In the groups with only three or twoTable 1 Description of the women at recruitment, %
<55 56–59 Total







Married or cohabiting 63 63 63
Divorced or widow 29 32 30
Single or missing 8 6 7
Education
primary/basic 7 9 8
secondary 35 28 31
vocational 30 27 28
university 28 36 33
Urban 73 74 73
Total 100 100 100measurements or intermittently, the proportion declined
over time. In the group having most follow-ups, the pro-
portion of women with bothersome symptoms first
increased and then decreased. In the group with three
follow-ups, the proportion first declined, and then
stayed about the same. Some women had symptoms
variably (i.e. having one or more measurements without
symptoms and then again reporting symptoms). Younger
women did not systematically have more bothersome
symptoms than older women.
Comparing the proportions of women with bother-
some symptoms at various times to those in the cross-
sectional analysis of Table 2 reveals relatively similar
percentages.
For comparison, we also studied psychological symp-
toms (depression and/or irritability) and pains (head,
back and/or joint pains; stomach) in the cross-sectional
analysis (Data not shown). The prevalence of bother-
some psychological symptoms (depression or irritability)
declined notably (by about half ) from recruitment to the
3-year follow-up, but there was very little change in the
prevalence of women reporting bothersome pains.Comments
About two thirds of the women in this selected group of
women reported vasomotor symptoms and about half
reported them being bothersome symptoms. There was
a notable variation in the development over time in the
prevalence of bothersome symptoms. The development
over time was related both to the timing of entering the
study, and the compliance with answering the surveys.
Table 3 Proportions (%) of women with bothersome vasomotor symptoms in past two weeks over time, by the
number of follow-ups women had (longitudinal analysis)
Recruitment 1-year 2-year 3-year 4-year
Women <55 (n = 182)
4 follow-ups (n = 11) 27.3 54.5 36.4 27.3 9.1
3 follow-ups (n = 44) 52.3 31.8 36.4 38.6 -
2 follow-ups (n = 48) 45.8 33.3 21.0 - -
1 follow-up (n = 16) 37.5 25.0 - - -
(% decline) (33.3) (100) - -
Intermittent surveys1 (n = 31) 48.4 44.4 25.0 9.1 20
Only recruitment (n = 32) 68.8 - - - -
All women (50–59) (n = 304)
4 follow-ups (n = 47) 40.4 51.1 31.9 27.7 23.4
3 follow-ups (n = 121) 39.7 24.0 27.3 22.3 -
2 follow-ups (n = 121) 42.1 34.7 23.1 - -
1 follow-up (n = 40) 40.0 30.0 - - -
(% decline) (25.0) - - -
Intermittent surveys 2 (n = 74) 54.1 36.8 17.6 16.4 6.8
Total (n = 486) 45.7 32.4 27.0 24.0 24.2
Only recruitment (n = 83) 57.8 - - - -
1 women participating in the specific survey included, n varies between 6–16.
2 women participating in the specific survey included, n varies between 19–74.
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to background characteristics to explain the variation.
The results of the longitudinal analysis (comparing the
same women over time) and those of the cross-sectional
analysis showed relatively similar results. Thus, we can
interpret the cross-sectional data as generally summing
up the experience of all women throughout the follow-
up, even though different women answered in different
surveys.
We had originally planned to make a longitudinal ana-
lysis using time-to-event calculations (event being the
end of symptoms) and estimate the duration of vaso-
motor symptoms. However, we did not have reliable data
of the duration of symptoms before recruitment and
complete measurements were not available for all
women. Furthermore the numbers of women in early
menopause were few.
These complications of data led us to the crude ana-
lysis used in the study. However, our analysis was good
enough to show the variability between women, and sug-
gest the need for larger follow-up studies to describe the
natural course of menopausal symptoms. To estimate
the duration of symptoms among unselected women
and to estimate the burden of symptoms related to
menopause, one would need a follow-up since meno-
pause in a population not using hormone therapy.
Our study women are not a representative sample of
women, but women who were motivated to join apreventive drug trial. A comparison of women wanting
and not wanting to join the trial showed that the studied
menopausal symptoms were four times more common
among those who initially expressed an interest than
among those who were not interested at the time of ask-
ing [25]. Thus, at a population level, the prevalence of
symptoms is much lower, but we know nothing of
whether the disturbance and variability among those
who have symptoms is the same as in our trial.
For comparison, we studied bothersome psychological
symptoms and pains in the cross-sectional analysis. The
psychological symptoms were less common, but other-
wise behaved as vasomotor symptoms; there was very lit-
tle change in the prevalence of women reporting
bothersome pains. If a longitudinal study on menopausal
women were to be made, other non-menopausal symp-
toms should also be studied.
As the overall balance of effects of postmenopausal
hormone therapy (HT) on chronic diseases is not posi-
tive (at the population level) [26] the use of HT is
argued largely on the basis of symptom relief. As the
current knowledge of the frequency or level of disturb-
ance of symptoms is patchy [14], population-based fol-
low-ups on the natural course of menopausal symptoms
are clearly needed. Even though such averaged informa-
tion does not accurately predict the fate of individual
women, it would be useful for women when they are try-
ing to decide whether or not to use HT. In the past such
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With the current knowledge on the mixed effect on dis-
eases, it might be feasible to find a representative cohort
of new menopausal women without HT for follow-up
studies.
Conclusion
There was a notable variability in the development of
disturbing vasomotor symptoms over time in a selected
group of women aged 50 -59. Population-based follow-
up studies of untreated women would be useful to esti-
mate the symptom burden.
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